1. Home
  2. JBL vs BIIB Comparison

JBL vs BIIB Comparison

Compare JBL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JBL
  • BIIB
  • Stock Information
  • Founded
  • JBL 1966
  • BIIB 1978
  • Country
  • JBL United States
  • BIIB United States
  • Employees
  • JBL N/A
  • BIIB N/A
  • Industry
  • JBL Electrical Products
  • BIIB Biotechnology: Pharmaceutical Preparations
  • Sector
  • JBL Technology
  • BIIB Health Care
  • Exchange
  • JBL Nasdaq
  • BIIB Nasdaq
  • Market Cap
  • JBL 21.7B
  • BIIB 24.2B
  • IPO Year
  • JBL 1993
  • BIIB 1991
  • Fundamental
  • Price
  • JBL $199.51
  • BIIB $169.74
  • Analyst Decision
  • JBL Strong Buy
  • BIIB Buy
  • Analyst Count
  • JBL 9
  • BIIB 24
  • Target Price
  • JBL $228.78
  • BIIB $174.62
  • AVG Volume (30 Days)
  • JBL 1.1M
  • BIIB 1.9M
  • Earning Date
  • JBL 12-17-2025
  • BIIB 10-30-2025
  • Dividend Yield
  • JBL 0.16%
  • BIIB N/A
  • EPS Growth
  • JBL N/A
  • BIIB N/A
  • EPS
  • JBL 5.92
  • BIIB 10.97
  • Revenue
  • JBL $29,802,000,000.00
  • BIIB $10,065,900,000.00
  • Revenue This Year
  • JBL $6.68
  • BIIB $2.97
  • Revenue Next Year
  • JBL $5.65
  • BIIB N/A
  • P/E Ratio
  • JBL $33.59
  • BIIB $15.38
  • Revenue Growth
  • JBL 3.18
  • BIIB 4.77
  • 52 Week Low
  • JBL $108.66
  • BIIB $110.04
  • 52 Week High
  • JBL $237.14
  • BIIB $170.78
  • Technical
  • Relative Strength Index (RSI)
  • JBL 40.16
  • BIIB 72.52
  • Support Level
  • JBL $196.40
  • BIIB $151.83
  • Resistance Level
  • JBL $221.98
  • BIIB $169.00
  • Average True Range (ATR)
  • JBL 7.87
  • BIIB 6.16
  • MACD
  • JBL -2.00
  • BIIB 1.38
  • Stochastic Oscillator
  • JBL 9.83
  • BIIB 96.61

About JBL Jabil Inc.

Jabil Inc is a United States-based company engaged in providing manufacturing services and solutions. It provides comprehensive electronics design, production and product management services to companies in various industries and end markets.The Company derives its revenue from providing comprehensive electronics design, production and product management services. It operates in two segments. The Electronics Manufacturing Services (EMS) segment, which is the key revenue driver, is focused on leveraging IT, supply chain design and engineering, technologies largely centered on core electronics. The Diversified Manufacturing Services (DMS) segment is focused on providing engineering solutions, with an emphasis on material sciences, technologies, and healthcare.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: